
Background Post-transplant lymphoproliferative disorders (PTLD) remain a major complication of solid organ transplants (SOT), occurring in 1%-10% of patients, but in greater proportions in children. About 50%-80% of cases are Epstein-Barr Virus (EBV) associated, through partially known and still unknown mechanisms. Even in EBV seronaive SOT recipients, transplant of an SOT from an EBV seropositive donor does not always lead to peripheral blood EBV replication. Longitudinal peripheral blood EBV DNA nucleic acid testing (NAT) after SOT has not improved the individual prediction of PTLD occurrence, likely due to variable SOT recipient immune responses.Methods This prospective study is designed to assess longitudinal and comprehensive T and NK cell phenotyping and responses to peripheral blood EBV replication via multispectral flow cytometry and other assays. We will also compare local to central EBV NAT values and test whether torquetenovirus NAT can act as a simpler assay to predict EBV clearance. We will collect 1390 blood samples across 5 time points in the first year after 347 enrolled (278 completed) SOTs (kidney, liver, heart, lung or intestine) from three major pediatric SOT centers in the U.S.A.Results As of June 30, 2025, our study has enrolled 133 participants, of whom 110 have received an organ transplant (27% Hispanic ethnicity, 16% black race, median age 8 years, across all 4 major SOT types).Conclusions By study end, we will know the global immune responses to EBV replication across a spectrum of clinical pediatric SOT situations. We expect to find key immune mechanisms that will predict poor or delayed EBV clearance despite clinical interventions. These findings may lead to new translational immunotherapy approaches to treat EBV DNaemia or prevent PTLD. We expect that our findings will also inform EBV oncogenesis in other immunocompromised or immunocompetent populations.
ABSTRACT Background There is a paucity of data on how to manage children with failed kidney transplants in order to optimize their access to future transplants. Our objective was to understand how system‐level differences in transplant care and immunosuppression management after graft failure are associated with access to a second kidney transplant in children. Methods To achieve our objective, we surveyed US pediatric kidney transplant centers about their practices. We then examined the relation between each center's approach in delivering follow‐up care, transitioning care, and immunosuppression management after graft failure with access of children to re‐transplantation between 2005 and 2019 according to the US Renal Data System using Fine‐Gray models. Results 43/84 surveyed programs who served 1388 pediatric patients with graft failure responded. Although programs had variable practices in terms of frequency of follow‐up visits and age of transition from pediatric to adult care, these practices were not associated with access to re‐transplantation. Regarding immunosuppression management, pediatric kidney transplant recipients at centers whose respondents did not oversee the weaning of immunosuppression after graft failure had a 37% reduced likelihood of re‐transplantation (95% CI: 17%–53%). Centers that continued immunosuppression in children receiving dialysis after graft failure until there was no residual graft function had a 39% reduced likelihood of re‐transplantation (95% CI: 17%–55%) compared to centers that withdrew immunosuppression after a pre‐defined period. Conclusions Management of pediatric transplant recipients with graft failure is variable at US pediatric kidney transplant centers, and variability in immunosuppression management practices was associated with the likelihood of re‐transplantation.
ABSTRACT Pediatric deceased organ donation raises distinct ethical challenges involving death determination, parental authority, and emerging organ recovery and preservation technologies. Although many of these controversies extend beyond pediatrics, they are shaped by a context in which authorization rests with parents, donation is rare and technically complex, and families are navigating the loss of their child. This review synthesizes established and emerging controversies in deceased organ donation through a pediatric lens, examining definitions and determinations of death, conflicts between end‐of‐life care and organ preservation, societal and individual trust, the distinction between authorization and informed consent, normothermic regional perfusion, and the dead donor rule as the foundation of deceased donation. The controversies reflect a central tension: the desire to save lives through organ transplantation and the obligation to protect the dying child from harm. As transplantation medicine evolves, the ethical frameworks guiding donation must continue to adapt to protect donors, support families, and maintain public trust.